Parnax Lab Limited Stock Price Today (NSE: PARNAXLAB)
Fundamental Score
Parnax Lab Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Parnax Lab Limited share price today is ₹120.26, down 2.91% on NSE/BSE as of 16 September 2026. Parnax Lab Limited (PARNAXLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹172.57 (Cr). The 52-week high for PARNAXLAB share price is ₹149.50 and the 52-week low is ₹104.00. At a P/E ratio of 13.48x, PARNAXLAB is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 14.36% and a debt-to-equity ratio of 0.87.
Parnax Lab Limited Share Price Chart — NSE/BSE Historical Performance
Parnax Lab Limited share price chart: -5.52% return over the past month. 52-week high ₹149.50, 52-week low ₹104.00.
Parnax Lab Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹123.00 | ₹123.90 | ₹117.05 | ₹120.26 | 2.00K (Cr) | |
| ₹127.00 | ₹127.00 | ₹122.72 | ₹123.87 | 1.73K (Cr) | |
| ₹127.48 | ₹134.72 | ₹125.00 | ₹127.00 | 3.08K (Cr) | |
| ₹141.70 | ₹149.50 | ₹104.00 | ₹127.48 | 1.78K (Cr) | |
| ₹116.00 | ₹134.95 | ₹116.00 | ₹130.00 | 1.92K (Cr) | |
| ₹126.73 | ₹129.35 | ₹125.15 | ₹125.90 | 2.68K (Cr) | |
| ₹134.99 | ₹136.80 | ₹122.05 | ₹132.99 | 337.00 (Cr) | |
| ₹135.54 | ₹135.54 | ₹130.00 | ₹134.80 | 736.00 (Cr) | |
| ₹144.95 | ₹144.95 | ₹134.80 | ₹135.54 | 8.00K (Cr) | |
| ₹143.00 | ₹144.90 | ₹134.01 | ₹137.23 | 9.20K (Cr) |
Parnax Lab Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹130.00 | ₹149.50 | ₹104.00 | ₹120.26 | -7.49% | |
| ₹135.25 | ₹138.00 | ₹108.03 | ₹132.00 | -2.40% | |
| ₹136.35 | ₹161.50 | ₹131.80 | ₹135.00 | -0.99% | |
| ₹126.50 | ₹146.95 | ₹117.00 | ₹136.35 | +7.79% | |
| ₹161.00 | ₹182.00 | ₹138.35 | ₹142.95 | -11.21% | |
| ₹126.00 | ₹169.00 | ₹126.00 | ₹160.00 | +26.98% | |
| ₹121.65 | ₹146.80 | ₹109.50 | ₹128.55 | +5.67% | |
| ₹122.95 | ₹135.00 | ₹114.00 | ₹131.45 | +6.91% | |
| ₹130.00 | ₹131.80 | ₹99.20 | ₹121.40 | -6.62% | |
| ₹120.25 | ₹140.00 | ₹106.90 | ₹130.00 | +8.11% | |
| ₹127.10 | ₹142.00 | ₹118.50 | ₹123.25 | -3.03% | |
| ₹136.00 | ₹136.00 | ₹120.80 | ₹129.00 | -5.15% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Parnax Lab Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Parnax Lab Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PARNAXLAB across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 13.48 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (41.99%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (22.51% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (94.19% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (105.43% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (72.29%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
4 factors identified
Profit Decline Concern (-20.23%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Liquidity Concerns (Current Ratio: 0.92)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Negative Free Cash Flow (₹-5.20 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Parnax Lab Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Parnax Lab Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Parnax Lab LimitedParnax Lab Limi...Selected✓ PARNAXLAB • 506128 | 55.1/100 | ₹120.26₹120 | ₹172.57₹172.57 | 13.48Average 13.5 Average | 14.36%Average 14.36% Average | 13.89%Average 13.89% Average | 0.87Good 0.9 Good | 105.43%Excellent 105.43% Excellent | 22.51%Excellent 22.51% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9425.50₹9426 | ₹249775.75₹249775.75 | 85.52Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.00₹1370 | ₹110675.45₹110675.45 | 32.82Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1925.50₹1926 | ₹104025.14₹104025.14 | 95.04Average 95.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.20₹1675 | ₹96391.01₹96391.01 | 26.17Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2099.90₹2100 | ₹96017.92₹96017.92 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.40₹1141 | ₹95306.90₹95306.90 | 29.50Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2289.10₹2289 | ₹94539.83₹94539.83 | 46.25Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price249775.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110675.45 Cr
Parnax Lab Limited PE Ratio History
Historical price-to-earnings ratio for PARNAXLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹8.38 | ₹168.00 | 20x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Parnax Lab Limited Quarterly Performance
Latest quarterly metrics for PARNAXLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
41.99%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-20.23%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
22.51%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
105.43%
Compounded annual net profit growth over 5 years
Parnax Lab Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PARNAXLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Parnax Lab Limited Financial Statements
Annual income statement, balance sheet and cash flow for Parnax Lab Limited (PARNAXLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Parnax Lab Limited
About PARNAXLAB (Parnax Lab Limited)
Parnax Lab Ltd is a pioneering force within the pharmaceutical industry, dedicated to advancing healthcare solutions through innovative research, development, and manufacturing. Wi...th a steadfast commitment to quality and efficacy, Parnax Lab specializes in creating a diverse portfolio of pharmaceutical products designed to address a wide spectrum of medical needs. The company’s state-of-the-art facilities adhere to stringent global regulatory standards, ensuring the production of safe and reliable medications that meet the highest benchmarks of excellence. Parnax Lab's driving mission is to enhance patient well-being by delivering accessible and affordable pharmaceutical products that improve lives around the world. Parnax Lab's product range encompasses a comprehensive array of therapeutic categories, catering to diverse patient populations and healthcare requirements. From advanced treatments for chronic conditions to essential medications for everyday ailments, Parnax Lab is committed to providing comprehensive healthcare solutions. Specifically, Parnax Lab excels in developing and manufacturing specialized treatments including; liquid suspensions, soothing topical ointments, skin rejuvenating creams, and convenient tablet and capsule forms. This diverse manufacturing capability allows for the development of treatments for a broad range of medical conditions including digestive issues, and pediatric formulations. Parnax Lab continues to push the boundaries of pharmaceutical innovation to create products that are truly life-changing. Driven by a passion for scientific discovery and a relentless pursuit of excellence, Parnax Lab fosters a culture of innovation and collaboration among its team of experienced scientists, researchers, and healthcare professionals. Parnax Lab maintains a strong emphasis on ethical practices and environmental responsibility throughout its operations, striving to create a sustainable and socially responsible business. With a global outlook and a local focus, Parnax Lab is dedicated to building lasting partnerships with healthcare providers, distributors, and patients to ensure that its products reach those who need them most, making a tangible difference in healthcare outcomes.
Company Details
Key Leadership
PARNAXLAB Share Price: Frequently Asked Questions
What is the current share price of Parnax Lab Limited?
Parnax Lab Limited (PARNAXLAB) trades at ₹120.26 on NSE and BSE. Market cap ₹172.57 (Cr). Educational data only.
What is the P/E ratio of Parnax Lab Limited?
Parnax Lab Limited has a P/E of 13.48x vs industry average 34.89x.
What is the Bull Run score for Parnax Lab Limited?
Parnax Lab Limited has a Bull Run score of 55.1/100 based on 25+ financial parameters.
Does Parnax Lab Limited pay dividends?
Parnax Lab Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Parnax Lab Limited?
Parnax Lab Limited has ROE of 14.36%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Parnax Lab Limited?
Parnax Lab Limited has debt-to-equity of 0.87.
Is Parnax Lab Limited a good investment?
Bull Run gives Parnax Lab Limited a score of 55.1/100. This is not investment advice — consult a SEBI-registered advisor.